New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs

Carlos   Alberto   Manssour Fraga; Eliezer   J.   Barreiro

Abstract

Some physiopathological processes involved in the genesis of diseases could suggest the necessity of designing bioligands or prototypes that aggregate, in only one molecule, dual pharmacodynamical properties, becoming able to be recognized by two elected bioreceptors. This approach can have distinct aspects and, when a novel ligand or a prototype acts in two elected targets belonging to the same biochemical pathway, e.g. arachidonic acid cascade, it receives the denomination of dual or mix agent. On the other hand, if these two targets belong to distinct biochemical routes and both are related to the same disease, we can characterize the agents able to modulate it as symbiotic ligands or prototypes. In the present work, we provide some examples and applications of the molecular hybridization concept for the structural design of new symbiotic ligands and prototypes, especially those applied in the treatment of chronic-degenerative disorders.

Keywords: Symbiotic drugs, molecular hybridization, multifactorial diseases, therapeutic innovation, drug design, dual compounds